HLA CW3 and HLA CW4 have a protective effect on acquisition of chronic myeloid leukemia on Mexican patients

Revista de Investigacion Clinica

Volumn 55, Issue 4, 2003, Pages 423-428

  Rosas Cabral, Alejandro ^a,b   Irigoyen, Lourdes ^a   Alvarado, Lilia ^a   Vela Ojeda, Jorge ^a   Ayala Sánchez, Manuel ^a   Tripp Villanueva, Francisco ^a   Sánchez, Evelia ^a   Gonzalez Llaven, José ^a   Gariglio, Patricio ^b  

^a HOSPITAL DE ESPECIALIDADES   (Mexico)

^b DEPARTAMENTO DE FÍSICA   (Mexico)

Author keywords

bcr abl; Chronic myeloid leukemia; HLA

Indexed keywords

BCR ABL PROTEIN; GENE PRODUCT; HLA A ANTIGEN; HLA A11 ANTIGEN; HLA A3 ANTIGEN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HLA B8 ANTIGEN; HLA C ANTIGEN; HLA CW3 ANTIGEN; HLA CW4 ANTIGEN; HLA DR ANTIGEN; HLA DR14 ANTIGEN; HLA DR3 ANTIGEN; HYBRID PROTEIN; PEPTIDE DERIVATIVE; PROTEIN TYROSINE KINASE; SYNTHETIC PEPTIDE; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AMINO ACID SEQUENCE; ANTIGEN BINDING; ANTIGEN EXPRESSION; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CAUCASIAN; CHROMOSOME TRANSLOCATION 22; CHROMOSOME TRANSLOCATION 9; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; ENZYME ACTIVITY; EUROPE; FEMALE; GENE FREQUENCY; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; MEXICO; PHENOTYPE; PROTEIN EXPRESSION; RISK ASSESSMENT; STATISTICAL ANALYSIS; TUMOR IMMUNITY;

ADOLESCENT; ADULT; FEMALE; HLA-C ANTIGENS; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MALE; MEXICO; MIDDLE AGED;

EID: 0345329508     PISSN: 00348376     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Rowley JD. A new consistent chromosome abnormality in chronic myelogenous leukemia. Nature 1973; 243: 209.
2. DeKlein A, Van Kessel AG, Grosveld G, Bartram CR, Hagemejier A, Bootsma D, Spurr NK, Heisterkamp N, Groffen J, Stephenson JR. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukemia. Nature 1982; 300: 765.
3. Kurzrock R, Gutterman JU, Talpaz M. The molecular genetics of Philadelphia chromosome positive leukemias. New Engl J Med 1988; 319: 990-8.
4. Barret A, Jiang YZ. Immune response to chronic myeloid leukemia. Bone Marrow Transplantation 1992; 198: 1205.
5. Grosveld G, Verwoerd T, Van Agthoven T. The chronic myelocytic cell line K562 contains a breakpoint in bcr and produces a chimeric bcr/abl transcript. Moll Cell Biol 1986; 6: 607-16.
6. Shitvelman E, Lifshitz B, Gale RP, Canaani E. Fused transcripts of abl and bcr genes in chronic myelogenous leukemia. Nature 1985; 315: 550-4.
7. Chen W, Peace DJ, Rovira DK, You SG, Cheever MA. T-cell immunity to the joining region of the p210 bcr-abl protein. Proc Natl Acad Sci USA 1992; 169: 87-98.
8. Bocchia M, Wentworth PA, Southwood S, Sidney J, McGraw K. Sheinberg DA. Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules. Blood 1995; 85: 2680.
9. Dermine S, Molldrem J, Parker KC, Jiang YZ, Mavoudis D, Hensel N, Couriel D, Mahoney M, Coligan JE, Barret AJ. Blood 1995; 86: 158a.
10. Van Denderen J, Hermans A, Meewsen T, Trelkstra C, Zegers N, Boersma W, et al. Antibody recognition of the tumor specific bcr-abl joining region in chronic myeloid leukemia. J Exp Med 1989; 169: 1468-72.
11. Bocchia M, Korontsvist T, Xu Q, Mackinnon S, Yang SY, Sette A, et al. Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood 1996; 87: 3587.
12. Amiel JL. Study of the leukocyte phenotypes in Hodgkin's disease. In: Curtoni ES, Mattiuz PL, Tosi EM (eds.). Histocompatibility testing 1967. Baltimore: Williams & Wilkins; 1967, p. 79-86.
13. Bortin M, D'Amaro J, Bach FH, Rimm AA, Van Rood J. HLA association with leukemia. Blood 1987; 70: 227-32.
14. Cortes J, Fayad I, Kantarjian H, O'Brien SO, Lee MS, Talpaz M. Association of HLA phenotype and response to interferon alpha in patients with chronic myelogenous leukemia. Leukemia 1998; 12: 455-62.
15. Dorak MT, Chalmers EA, Gafney D, Wilson DWL, Galbraith I, Henderson N, et al. Human major hystocompatibility complex contains several leukemia susceptibility genes. Leukemia Lymp 1994; 12: 211-22.
16. Caruso C, Cammarata G, Sireci G, Modica M.A. HLA-Cw4 association with acute lymphoblastic leukemia in Sicilian patients. Vox Sang 1988; 54: 57-8.
17. Pollack MS, DuBois D. Possible effects of non-HLA antibodies in common typing sera on HLA antigen frequency data in leukemia. Cancer 1977; 39: 2348.
18. Hester JP, Rossen R, Trujillo J, McCredie KB, Freireich EJ. Frequency of HLA antigens in chronic myelocytic leukemia. South Med J 1977; 70(6): 691-3.
19. D'Amaro J, Bach FH, Van Rood JJ, Rimm AA, Bortin M. HLA C associations with acute leukemia. Lancet 1984; 2(8413): 1176-8.
20. McCloskey DJ, Brown J, Navarrete C. Serological typing of HLA-A, -B, and -C antigens. In: M Hui and JL Bidwell (eds.). Handbook of HLA typing techniques. Boca Ratón, FL: CRC Press; 1972 p. 175-247.
21. Woolf B. On estimating the relation between blood groups and disease. Ann Hum Genet 1995; 19: 251-3.
22. Svejgaard A, Platz Pand Ryder LP. HLA and disease 1982: A survey. Immunol Rev 1993; 20: 193-217.
23. Lilly F, Boyse EA and Old LJ. Genetic basis of susceptibility to viral leukaemogenesis. Lancet 1964; ii: 1207-9.
24. Tiwari JL, Terasaki PI. The HLA complex. In: Tiwari JL and Terasaki PI (eds.). HLA and disease associations. New York, NY: Springer-Verlag; 1985; 4-17.
25. Gonzalez-Llaven J, Sánchez-Cortés E, Zaragoza G, Rodriguez-Castillo P, Palomares B, Marín-Palomares T, et al. Incidencia-prevalencia de enfermedades oncohematológicas en la Región Norte de La Raza. Registro de tres años 1991-1993. Estudio Multicéntrico. XXXVIII Jornadas Agrupación Mexicana para el Estudio de La Hematología. 19a, 1997.
26. Registro Histopatológico de Neoplasias en México. 1997
27. Hernández JA, Land KJ, McKenna RW. Leukemias, myeloma, and other lymphoreticular neoplasms. Cancer 1995; 75: 381-94.
28. Bishara A, Brautbar C, Nagler A. HLA and graft-versus-host disease: a population-based study of HLA phenotypes of Jewish and Arabic bone marrow transplanted patients in Israel. Leuk Res 1997; 2: 111-8.
29. Dorak MT, Machulla HKG, Hentshel M, Mills KI, Langner J. Influence of the major histocompatibility complex on age at onset of chronic lymphoid leukemia. Int J Cancer 1996; 65: 134-9.
30. Vasmel WLE, Zijlstra M, Radaskiewicz T, Leupers CJM, De Goede REY, Melief CJM. Major hystocompatibility complex class-II-regulated immunity to murine leukemia virus protects against early T- but not late B-cell lymphomas. J Virol 1998; 62: 3156-66.
31. Posthuma EFM, Falkenburg JHF, Apperly JF, Gratwohl A, Roosnek E, Hertenstein B, et al. Niederwieser D on behalf of the Chronic Leukemia Working Party of the EBMT. HLA-B8 and HLA-A3 coexpressed with HLA-B8 are associated with a reduced risk of the development of chronic myeloid leukemia. Blood 1999; 11: 3863-5.